Tests a glucose sensor device for people with type 2 diabetes
Compares a FreeStyle Libre glucose sensor with usual monitoring in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Patient-Driven Lifestyle Modification Using FreeStyle Libre in Type 2 Diabetes Patients
Key facts
- Where
- Seoul, South KoreaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 80 years old?
Source: NCT04932928, who can take part
Where in South Korea
- Seoul National University HospitalSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Seoul National University Hospital
- Trial code
- NCT04932928
- Record updated
- 21 June 2021
- Original description
We aim to provide medical nutritional therapy to patients with type 2 diabetes who are on oral hypoglycemic agents or on basal insulin only and monitor the glycemic response with flash glucose monitoring or self-monitoring of blood glucose.Read full original descriptionShow less
Patient-Driven Lifestyle Modification Using FreeStyle Libre in Type 2 Diabetes Patients
We aim to provide medical nutritional therapy to patients with type 2 diabetes who are on oral hypoglycemic agents or on basal insulin only and monitor the glycemic response with flash glucose monitoring or self-monitoring of blood glucose.
Specifically, this is a randomized, open-label, controlled study where half of the study participants will have FreeStyle Libre device on for 12 weeks and compare the change in glycated hemoglobin (HbA1c) value with the patients in the control group.
Inclusion: Age 19-80; Diagnosed with type 2 diabetes mellitus (DM); Uncontrolled type 2 DM: HbA1c 7.0-10.0%; Signed informed consent.
Exclusion: Addiction to drugs and alcohol; Use of medications that result in drug-induced hyperglycemia (i.e. steroid); Diagnosed with other types of diabetes mellitus (i.e. Type 1 DM); Change in diabetes medication in the preceding 3 months; Severe liver disease; End-stage renal disease (i.e. on dialysis); Unable to wear CGM devices due to dermatologic side effects (i.e. severe burn, inflammation, active skin infection, severe skin reactions, hypertrichosis, etc.); Conditions that impact the stability of HbA1c measurement; Use of prandial insulin; Pregnant/lactating women.